APOLLO: SLN360 Clears First Major Hurdle, Hammering Lp(a)
The results add to growing enthusiasm for achieving the 'holy grail' of a lipoprotein(a)-specific lowering agent, but whether it will reduce cardiovascular risk remains unknown.
Medscape Medical News
source https://www.medscape.com/viewarticle/971491?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/971491?src=rss
Comments
Post a Comment